Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone IPCA Titration Conversion to Hydromorphone ER Tablets in Severe Cancer Pain
ChiCTR2500112165Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of hydromorphone in cancer pain (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Average pain score on days 4-6. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2500112165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112165.